Publications [#132174] of James M Provenzale

Papers Published

1. G Akabani, I Cokgor, RE Coleman, D González Trotter, TZ Wong, HS Friedman, AH Friedman, A Garcia-Turner, JE Herndon, D DeLong, RE McLendon, XG Zhao, CN Pegram, JM Provenzale, DD Bigner, MR Zalutsky, Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy., International journal of radiation oncology, biology, physics, vol. 46 no. 4 (March, 2000), pp. 947-58, ISSN 0360-3016
   (last updated on 2011/07/12)

   Abstract:
   OBJECTIVE: The objective of this study was to perform the dosimetry and evaluate the dose-response relationships in newly diagnosed patients with malignant brain tumors treated by direct injections of (131)I-labeled 81C6 monoclonal antibody (MAb) into surgically created resection cavities (SCRCs). METHODS: Absorbed doses to the 2-cm-thick shell as measured from the margins of the resection cavity interface were estimated for 42 patients with primary brain tumors. MR images were used to assess the enhanced-rim volume as a function of time after radiolabeled MAb therapy. Biopsy samples were obtained from 15 patients and 1 autopsy. RESULTS: The average absorbed dose [range] to the 2-cm shell region was 32 [3-59] Gy. For the endpoint of minimal time to MR contrast enhancement, the optimal absorbed dose and initial dose-rate were 43 +/- 16 Gy and 0. 41 +/- 0.10 Gy/h, respectively. There was a correlation between the absorbed dose and dose rate to the shell region and biopsy outcome (tumor recurrence, radionecrosis, and tumor recurrence and/or radionecrosis). In this Phase I study, the maximum tolerated dose (MTD) was 120 mCi. At this MTD, the estimated average absorbed dose and initial dose rate to the 2-cm shell were 41 [9-89] Gy and 0.51 [0.24-1.13] Gy/h, respectively. These values are in agreement with the optimal values based on the time to MR lesion rim enhancement. CONCLUSIONS: The average absorbed dose to the 2-cm shell region varied considerably and mainly depended on cavity volume. In future clinical trials, the administered activity of (131)I-labeled 81C6 MAb may be adjusted based on cavity volume in order to deliver the optimal absorbed dose of 43 Gy rather than giving a fixed administered activity.

   Keywords:
   Antibodies, Monoclonal • Brain Neoplasms • Dose-Response Relationship, Radiation • Female • Glioma • Humans • Iodine Radioisotopes • Magnetic Resonance Imaging • Male • Middle Aged • Radioimmunotherapy • Tenascin • immunology* • methods* • radiotherapy* • therapeutic use*